Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220728 | 0.81 | MAPT (0.47) | MAPTGAAHTR1AKMT2AMEN1 | |
| SCHEMBL13804292 | 0.79 | CYP1A2 (0.43) | KMT2AMEN1SMN1; SMN2HSD17B10VNN1 | |
| SCHEMBL26691487 | 0.79 | MAPT (0.46) | MAPTGAAHTR1AKMT2AMEN1 | |
| SCHEMBL13804168 | 0.78 | ALDH1A1 (0.48) | KMT2AMEN1VNN1ALDH1A1TSHR | |
| SCHEMBL23329475 | 0.76 | AOC2 (0.37) | GAAKMT2AVNN1ALDH1A1DRD2 | |
| SCHEMBL23691788 | 0.76 | POLB (0.53) | GAAKMT2AMEN1POLBALDH1A1 | |
| SCHEMBL282864 | 0.75 | — | — | |
| SCHEMBL24341888 | 0.74 | MAPT (0.42) | MAPTGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL25094300 | 0.74 | MAPT (0.46) | MAPTGAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL24300501 | 0.74 | CYP2D6 (0.50) | KMT2AMEN1HSD17B10ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023281-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, AGTR1 | MAPT 4581/4885GAA 4430/4885HTR1A 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.